BioSpace News Archive

Immix Biopharma, Inc., a biopharmaceutical company pioneering Tissue-Specific Therapeutics ™ targeting oncology and immuno-dysregulated diseases, confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank or Silvergate Bank.

Mirum Pharmaceuticals, Inc. announced that on March 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 40,050 shares of common stock and 20,050 restricted stock units to four new employees under Mirum’s 2020 Inducement Plan.

Rakovina Therapeutics Inc. announces that it may apply to the TSX Venture Exchange to extend the expiry date of 11,414,750 common share purchase warrants issued by the Company.

Acadia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved DAYBUE™ for the treatment of Rett syndrome in adult and pediatric patients two years of age and older.

Tango Therapeutics, Inc. reported that it is aware of the current situation affecting Silicon Valley Bank, it is monitoring this situation closely and does not expect its exposure to SVB will require any change to its previously provided guidance that it has sufficient cash, cash equivalents and marketable securities to fund operations into 2025.